Indian Pharma industry moving towards formulations

Indian Pharma industry is slowing moving up the value chain. Earlier it used to manufacture active pharmaceutical ingredient at low cost compared to world. Now with competition from China, which provides API at 15-20% low cost, it makes sense to shift focus elsewhere. Many top companies like Lupin, Novartis, Ranbaxy have less revenue stream from API than from formulations. There could also be the reason that formulation business has grown faster than APIs for some companies. API is low scale commodity with low margin. Moreover, with a large number of patent expiries in developed markets like the US and Europe, Indian companies, with skills to develop and manufacture low-cost generic drugs, see a much more lucrative opportunity there than utilising their capacities for manufacturing APIs.
Read More

  • No Image
    GVK Biosciences Pvt Ltd

    GVK Biosciences (GVK BIO) is one of Asia?s leading Discovery Research and Development organizations. GVK BIO provides a broad spectrum of services, across the R&D and manufactur

  • No Image
    Hatri Pharma Pvt Ltd

    Hatri Pharma Pvt Ltd is an integrated API manufacturing company established in 2013 has its manufacturing facility located in Vinjamur Village & Mandal, SPSR Nellore Dist at And

  • No Image
    Hester Biosciences Ltd

    Hester Biosciences Limited is a WHO-GMP, ISO 9001:2008, ISO 14001:2004, OHSAS 18001:2007 & GLP certified company, manufacturing animal vaccines and health products. Located near

  • No Image
    Hetero Drugs Ltd

    Hetero is one of India?s leading generic pharmaceutical companies and is one of the world?s largest global producer of anti-retroviral drugs for the treatment of HIV/AIDS. Found